Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy

References

• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2163–2196.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the united states a policy statement from the american heart association. Circ Heart Fail. 2013;6:606–619.
   PubMed Web of Science ®Google Scholar
• Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368–378.
   PubMed Web of Science ®Google Scholar
• Liu T, Song D, Dong J, et al. Current understanding of the pathophysiology of myocardial fibrosis and its quantitative assessment in heart failure. Front Physiol. 2017;8:1–13.
   PubMed Web of Science ®Google Scholar
• Kim GH, Uriel N, Burkhoff D. Reverse remodelling and myocardial recovery in heart failure. Nat Rev Cardiol. 2018;15:83–96.
   PubMed Web of Science ®Google Scholar
• Hochman J, Bulkley B. Expansion of acute myocardial infarction: an experimental study. Circulation. 1982;65:1446–1450.
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Giamouzis G, Boudoulas KD, et al. Left ventricular geometry as a major determinant of left ventricular ejection fraction: physiological considerations and clinical implications. Eur J Heart Fail. 2018;20:436–444.
   PubMed Web of Science ®Google Scholar
• MacIver DH. The relative impact of circumferential and longitudinal shortening on left ventricular ejection fraction and stroke volume. Exp Clin Cardiol. 2012;17:5–11.
   PubMedGoogle Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018;1–16.
   Google Scholar
• Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73:1931–1944.
   PubMed Web of Science ®Google Scholar
• Mor-Avi V, Lang R, Badano L, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011;24:277–313.
   PubMed Web of Science ®Google Scholar
• Santos-Gallego C, Vahl T, Goliasch G, et al. Sphingosine-1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia/reperfusion. Circulation. 2016;133:954–966.
   PubMed Web of Science ®Google Scholar
• Ibanez B, Prat-González S, Speidl WS, et al. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation. 2007;115:2909–2916.
   PubMed Web of Science ®Google Scholar
• Amundsen B, Helle-Valle T, Edvardsen T, et al. Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging. J Am Coll Cardiol. 2006;47:789–793.
   PubMed Web of Science ®Google Scholar
• Garcia-Ropero A, Santos-Gallego CG, Zafar MU, et al. Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opin Drug Metab Toxicol. 2019;1–11.
   PubMed Web of Science ®Google Scholar
• Russo C, Jin Z, Elkind M, et al. Prevalence and prognostic value of subclinical left ventricular systolic dysfunction by global longitudinal strain in a community-based cohort. Eur J Heart Fail. 2014;16:1301–1309.
   PubMed Web of Science ®Google Scholar
• Kalam K, Otahal P, Marwick T. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014;100:1673–1680.
   PubMed Web of Science ®Google Scholar
• Pryds K, Larsen A, Hansen M, et al. Myocardial strain assessed by feature tracking cardiac magnetic resonance in patients with a variety of cardiovascular diseases - A comparison with echocardiography. Sci Rep. 2019;9:11296.
   PubMed Web of Science ®Google Scholar
• Muser D, Castro SA, Santangeli P, et al. Clinical applications of feature-tracking cardiac magnetic resonance imaging. World J Cardiol. 2018;10:210–221.
   PubMed Web of Science ®Google Scholar
• Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2014;27:911–939.
   PubMed Web of Science ®Google Scholar
• Sabatino J, De Rosa S, Tammè L, et al. Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol. 2020;19(1):66.
   PubMed Web of Science ®Google Scholar
• Smiseth OA, Torp H, Opdahl A, et al. Myocardial strain imaging: how useful is it in clinical decision making? Eur Heart J. 2016;37:1196–1207b.
   PubMed Web of Science ®Google Scholar
• Li Z, Agrawal V, Ramratnam M, et al. Cardiac sodium-glucose co-transporter 1 (SGLT1) is a novel mediator of ischemia/reperfusion injury. Cardiovasc Res. 2019;115:1646–1658.
   Web of Science ®Google Scholar
• Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298–310.
   PubMed Web of Science ®Google Scholar
• Kang S, Verma S, Teng G, et al. Direct effect of empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: novel translational clues to EMPA-REG OUTCOME. Abstract Can J Cardiol. 2017;33:S169.
   Google Scholar
• Hutchinson K, Saripalli C, Chung C, et al. Increased myocardial stiffness due to cardiac titin isoform switching in a mouse model of volume overload limits eccentric remodeling. J Mol Cell Cardiol. 2015;79:104–114.
   PubMed Web of Science ®Google Scholar
• Linke W. Sense and stretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. Cardiovasc Res. 2008;77:637–648.
   PubMed Web of Science ®Google Scholar
• LeWinter M, Granzier H. Cardiac titin and heart disease. J Cardiovasc Pharmacol. 2014;63:207–212.
   PubMed Web of Science ®Google Scholar
• Paraskevaidis IA, Farmakis D, Papadopoulos C, et al. Two-dimensional strain analysis in patients with hypertrophic cardiomyopathy and normal systolic function: a 12-month follow-up study. Am Heart J. 2009;158:444–450.
   PubMed Web of Science ®Google Scholar
• Murtaza G, Virk HUH, Khalid M, et al. Role of speckle tracking echocardiography in dilated cardiomyopathy: a review. Cureus. 2017;9.
   Web of Science ®Google Scholar
• Flores E, Santos-gallego CG, Diaz-mejía N, et al. Do the SGLT-2 inhibitors offer more than hypoglycemic activity? Cardiovasc Drugs Ther. 2018;32:213–222.
   PubMed Web of Science ®Google Scholar
• García-Ropero A, Santos-Gallego C, Badimon J. The anti-inflammatory effects of SGLT inhibitors. Aging (Albany NY). 2019;11:5866–5867.
   PubMedGoogle Scholar
• Scheen A. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics. Diabetes Metab. 2016;42:224–233.
   PubMed Web of Science ®Google Scholar